Ciprofol Alleviates Depressive-Like Behaviors in CUMS Mice Through PPARα-Associated ERK/CREB Signaling Activation
Open Access
- 1 August 2025
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7553-7569
Abstract
Background: Depression is a complex neuropsychiatric disorder involving neuroinflammation, synaptic dysfunction, and neurotransmitter dysregulation. Recent studies have highlighted the therapeutic potential of short-acting anesthetics in the treatment of depression. Ciprofol, a novel intravenous anesthetic with rapid onset and recovery, shows promise, although its antidepressant mechanisms remain underexplored. Methods: We induced a depressive-like phenotype in mice using a 5-week chronic unpredictable mild stress (CUMS) protocol. Following model establishment, the mice received intraperitoneal injections of ciprofol (25 mg/kg) for 7 days. Behavioral assessments included the sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST). To investigate neuroinflammation and microglial activation in the prefrontal cortex (PFC), we employed immunofluorescence staining, three-dimensional reconstruction, and quantitative real-time PCR (qRT-PCR). Synaptic structural changes were assessed using Western blot, three-dimensional reconstruction, and Golgi staining. Furthermore, transcriptome sequencing and Western blot were performed to elucidate the potential mechanisms underlying the antidepressant effects of ciprofol. Results: Ciprofol treatment alleviated CUMS-induced depressive behaviors, as evidenced by reduced immobility time and increased sucrose preference. Ciprofol suppressed PFC microglial activation and downregulated pro-inflammatory cytokines, while preserving synaptic integrity by inhibiting microglia-mediated synaptic phagocytosis. Mechanistic studies suggested that ciprofol’s antidepressant effect might be mediated by PPARα activation, which potentially triggers the ERK/CREB pathway, as indicated by transcriptome analysis and Western blot. Conclusion: Ciprofol can alleviate the depressive-like behaviors in CUMS mice by inhibiting the inflammatory response and reducing synaptic loss, and the mechanism may be related to the activation of the PPARα-mediated ERK/CREB pathway.Keywords
This publication has 78 references indexed in Scilit:
- Microglia‐Derived Interleukin‐6 Triggers Astrocyte Apoptosis in the Hippocampus and Mediates Depression‐Like BehaviorAdvanced Science, 2025
- Transcriptomic Profile of the Male Rat Hypothalamus and Nucleus Accumbens After Paroxetine Treatment and Withdrawal: Possible Causes of Sexual DysfunctionMolecular Neurobiology, 2024
- Microglial EPOR Contribute to Sevoflurane-induced Developmental Fine Motor Deficits Through Synaptic Pruning in MiceNeuroscience Bulletin, 2024
- Nrf2 attenuates oxidative stress to mediate the protective effect of ciprofol against cerebral ischemia–reperfusion injuryFunctional & Integrative Genomics, 2023
- Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese miceBrain, Behavior, and Immunity, 2022
- Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 TrialAdvances in Therapy, 2021
- Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanismsBrain, Behavior, and Immunity, 2018
- Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive EpisodesJAMA Psychiatry, 2015
- GABAergic Control of Depression-Related Brain States2015
- Reduced Prefrontal Glutamate/Glutamine and γ-Aminobutyric Acid Levels in Major Depression Determined Using Proton Magnetic Resonance SpectroscopyArchives of General Psychiatry, 2007